首页> 外文期刊>Neuropsychiatric Disease and Treatment >Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties
【24h】

Clinical utility of orally disintegrating olanzapine in Chinese patients with schizophrenia: a review of effectiveness, patient preference, adherence, and other properties

机译:口服崩解性奥氮平在中国精神分裂症患者中的临床应用:有效性,患者喜好,依从性和其他性质的综述

获取原文
           

摘要

Abstract: The primary objective of this systematic review was to examine the evidence for the efficacy, effectiveness, and safety of orally disintegrating olanzapine in Chinese populations. A systematic literature search was conducted using databases covering international and Chinese journals, ClinicalTrials.gov, and internal and external trial registries at Eli Lilly and Company using search terms related to target countries (People's Republic of China, Hong Kong, and Taiwan) and orally disintegrating olanzapine treatment. A publication and one clinical study report were retrieved. The clinical study showed orally disintegrating olanzapine and the standard oral tablet to have similar efficacy and tolerability profiles. A bioequivalence study has shown that orally disintegrating olanzapine and the standard oral tablet have similar pharmacokinetic profiles. Orally disintegrating olanzapine and the standard oral tablet have similar efficacy and tolerability profiles.
机译:摘要:本系统综述的主要目的是研究口服崩解奥氮平在中国人群中的有效性,有效性和安全性。使用涉及目标国家(中华人民共和国,香港和台湾)的相关搜索字词,使用涵盖国际和中文期刊,ClinicalTrials.gov以及礼来公司的内部和外部试验注册处的数据库,进行了系统的文献检索崩解奥氮平治疗。检索了一份出版物和一份临床研究报告。临床研究表明,口服崩解奥氮平和标准口服片剂具有相似的疗效和耐受性。生物等效性研究表明,口服崩解的奥氮平与标准口服片剂具有相似的药代动力学特征。口服崩解的奥氮平和标准口服片剂具有相似的功效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号